Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P00533
UPID:
EGFR_HUMAN
Alternative names:
Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
Alternative UPACC:
P00533; O00688; O00732; P06268; Q14225; Q68GS5; Q92795; Q9BZS2; Q9GZX1; Q9H2C9; Q9H3C9; Q9UMD7; Q9UMD8; Q9UMG5
Background:
The Epidermal Growth Factor Receptor (EGFR), also known as Proto-oncogene c-ErbB-1 and Receptor tyrosine-protein kinase erbB-1, plays a pivotal role in cellular signaling pathways. By binding ligands of the EGF family, it activates cascades such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, and others, influencing cell migration, proliferation, and differentiation.
Therapeutic significance:
EGFR's involvement in lung cancer and Inflammatory skin and bowel disease, neonatal, 2, underscores its potential as a therapeutic target. Its role in disease pathogenesis and cell entry facilitation for hepatitis C virus highlights the importance of EGFR modulation in treating these conditions.